BioRestorative Therapies (FRA:9OF) FCF Margin % : -9,941.18% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioRestorative Therapies's Free Cash Flow for the three months ended in Dec. 2023 was €-1.69 Mil. BioRestorative Therapies's Revenue for the three months ended in Dec. 2023 was €0.02 Mil. Therefore, BioRestorative Therapies's FCF Margin % for the quarter that ended in Dec. 2023 was -9,941.18%.

As of today, BioRestorative Therapies's current FCF Yield % is -75.59%.

The historical rank and industry rank for BioRestorative Therapies's FCF Margin % or its related term are showing as below:

FRA:9OF' s FCF Margin % Range Over the Past 10 Years
Min: -14422.22 Med: -4686.89 Max: -573.13
Current: -4537.04

During the past 13 years, the highest FCF Margin % of BioRestorative Therapies was -573.13%. The lowest was -14422.22%. And the median was -4686.89%.

FRA:9OF's FCF Margin % is ranked worse than
87.18% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs FRA:9OF: -4537.04

BioRestorative Therapies FCF Margin % Historical Data

The historical data trend for BioRestorative Therapies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies FCF Margin % Chart

BioRestorative Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-5,349.57

-2,561.90

-7,253.66

-5,307.08

-4,517.16

BioRestorative Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-43,300.00	-7,758.62	-1,783.33	-3,844.83	-9,941.18

Competitive Comparison of BioRestorative Therapies's FCF Margin %

For the Biotechnology subindustry, BioRestorative Therapies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's FCF Margin % falls into.

BioRestorative Therapies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioRestorative Therapies's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-6.053	/	0.134
	=	-4,517.16 %

BioRestorative Therapies's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.69	/	0.017
	=	-9,941.18 %

BioRestorative Therapies FCF Margin % Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies (FRA:9OF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BRTX:USA

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies (FRA:9OF) Headlines

No Headlines